A detailed history of Prospera Financial Services Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Prospera Financial Services Inc holds 13,498 shares of VRTX stock, worth $5.51 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
13,498
Previous 2,547 429.96%
Holding current value
$5.51 Million
Previous $1.19 Million 426.15%
% of portfolio
0.16%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$460.0 - $505.78 $5.04 Million - $5.54 Million
10,951 Added 429.96%
13,498 $6.28 Million
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $27,889 - $34,472
-71 Reduced 2.71%
2,547 $1.19 Million
Q1 2024

Aug 13, 2024

BUY
$407.69 - $446.08 $79,907 - $87,431
196 Added 7.7%
2,743 $1.15 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $17,493 - $20,944
-51 Reduced 1.91%
2,618 $1.07 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $12,850 - $13,773
38 Added 1.44%
2,669 $928,000
Q2 2023

Aug 08, 2023

BUY
$314.42 - $351.91 $1,257 - $1,407
4 Added 0.15%
2,631 $925,000
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $18,409 - $21,001
65 Added 2.54%
2,627 $827,000
Q4 2022

Feb 08, 2023

BUY
$285.76 - $321.48 $24,861 - $27,968
87 Added 3.52%
2,562 $739,000
Q3 2022

Oct 27, 2022

BUY
$273.83 - $305.53 $62,980 - $70,271
230 Added 10.24%
2,475 $716,000
Q2 2022

Aug 08, 2022

BUY
$234.96 - $292.55 $132,987 - $165,583
566 Added 33.71%
2,245 $633,000
Q1 2022

May 04, 2022

BUY
$221.42 - $260.97 $371,764 - $438,168
1,679 New
1,679 $438,000
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $32,500 - $43,346
-157 Closed
0 $0
Q3 2020

Nov 04, 2020

SELL
$255.65 - $303.1 $136,772 - $162,158
-535 Reduced 77.31%
157 $43,000
Q2 2020

Aug 07, 2020

BUY
$225.48 - $295.8 $156,032 - $204,693
692 New
692 $201,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Prospera Financial Services Inc Portfolio

Follow Prospera Financial Services Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prospera Financial Services Inc with notifications on news.